Clearbridge Investments LLC Has $143.10 Million Stock Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

Clearbridge Investments LLC cut its holdings in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 28.9% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 775,213 shares of the medical research company's stock after selling 315,779 shares during the period. Clearbridge Investments LLC owned 1.52% of Charles River Laboratories International worth $143,104,000 as of its most recent filing with the SEC.

Several other large investors have also made changes to their positions in the business. Fiduciary Financial Group LLC increased its position in Charles River Laboratories International by 3.9% in the 4th quarter. Fiduciary Financial Group LLC now owns 1,665 shares of the medical research company's stock worth $310,000 after buying an additional 63 shares during the period. Pinnacle Bancorp Inc. raised its stake in Charles River Laboratories International by 52.0% during the 4th quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company's stock valued at $35,000 after purchasing an additional 65 shares during the last quarter. M&T Bank Corp raised its stake in Charles River Laboratories International by 3.4% during the 3rd quarter. M&T Bank Corp now owns 2,001 shares of the medical research company's stock valued at $394,000 after purchasing an additional 66 shares during the last quarter. Cornerstone Investment Partners LLC boosted its holdings in Charles River Laboratories International by 3.7% in the 4th quarter. Cornerstone Investment Partners LLC now owns 1,940 shares of the medical research company's stock valued at $358,000 after purchasing an additional 69 shares during the period. Finally, Metis Global Partners LLC grew its position in Charles River Laboratories International by 4.4% in the 4th quarter. Metis Global Partners LLC now owns 1,720 shares of the medical research company's stock worth $318,000 after purchasing an additional 72 shares during the last quarter. Institutional investors and hedge funds own 98.91% of the company's stock.

Remove Ads

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on CRL shares. JPMorgan Chase & Co. decreased their target price on Charles River Laboratories International from $175.00 to $165.00 and set a "neutral" rating on the stock in a research report on Thursday, February 20th. Robert W. Baird lowered their price objective on Charles River Laboratories International from $177.00 to $173.00 and set a "neutral" rating on the stock in a research report on Thursday, February 20th. Morgan Stanley cut their target price on Charles River Laboratories International from $220.00 to $184.00 and set an "equal weight" rating for the company in a research note on Wednesday, February 5th. Citigroup upgraded shares of Charles River Laboratories International from a "sell" rating to a "neutral" rating and lifted their price target for the stock from $155.00 to $175.00 in a research note on Tuesday, March 4th. Finally, Bank of America dropped their price objective on shares of Charles River Laboratories International from $220.00 to $210.00 and set a "neutral" rating for the company in a research note on Friday, December 13th. One investment analyst has rated the stock with a sell rating and sixteen have assigned a hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $189.77.

Charles River Laboratories International Price Performance

CRL stock traded down $4.03 during midday trading on Friday, reaching $136.95. 1,666,195 shares of the company's stock traded hands, compared to its average volume of 770,520. The company has a 50-day simple moving average of $162.49 and a two-hundred day simple moving average of $180.95. The company has a quick ratio of 1.14, a current ratio of 1.41 and a debt-to-equity ratio of 0.65. Charles River Laboratories International, Inc. has a 1-year low of $132.99 and a 1-year high of $258.56. The company has a market cap of $7.00 billion, a price-to-earnings ratio of 912.99, a PEG ratio of 4.54 and a beta of 1.45.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last announced its earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.50 by $0.16. The company had revenue of $1 billion for the quarter, compared to analyst estimates of $983.63 million. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. Charles River Laboratories International's quarterly revenue was down 1.1% on a year-over-year basis. During the same period in the prior year, the business earned $2.46 earnings per share. On average, analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year.

Insider Buying and Selling

In other Charles River Laboratories International news, CEO James C. Foster bought 6,075 shares of the company's stock in a transaction on Thursday, February 20th. The stock was bought at an average price of $165.01 per share, for a total transaction of $1,002,435.75. Following the transaction, the chief executive officer now owns 183,639 shares of the company's stock, valued at approximately $30,302,271.39. The trade was a 3.42 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, COO Birgit Girshick purchased 1,514 shares of the business's stock in a transaction dated Thursday, February 20th. The stock was bought at an average cost of $164.63 per share, for a total transaction of $249,249.82. Following the purchase, the chief operating officer now owns 55,058 shares in the company, valued at $9,064,198.54. This trade represents a 2.83 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Corporate insiders own 1.30% of the company's stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).